Sanofi SA (EPA:SAN) received a €95.00 ($105.56) target price from investment analysts at J P Morgan Chase & Co in a research note issued on Thursday. The firm presently has a “neutral” rating on the stock.

A number of other equities analysts also recently issued reports on the company. Berenberg Bank set a €92.00 ($102.22) price target on Sanofi SA and gave the company a “buy” rating in a research note on Friday, April 28th. Morgan Stanley set a €91.00 ($101.11) price target on Sanofi SA and gave the company a “buy” rating in a research note on Monday, April 24th. Kepler Capital Markets set a €92.00 ($102.22) price target on Sanofi SA and gave the company a “buy” rating in a research note on Wednesday, April 12th. Deutsche Bank AG set a €96.00 ($106.67) price target on Sanofi SA and gave the company a “buy” rating in a research note on Tuesday, April 11th. Finally, Societe Generale set a €100.00 ($111.11) price target on Sanofi SA and gave the company a “buy” rating in a research note on Thursday, March 23rd. Two equities research analysts have rated the stock with a sell rating, ten have assigned a hold rating and four have issued a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus target price of €87.40 ($97.11).

Analyst Recommendations for Sanofi SA (EPA:SAN)

Shares of Sanofi SA (EPA SAN) opened at 87.35 on Thursday. The stock has a 50 day moving average price of €25.48 and a 200-day moving average price of €25.74. Sanofi SA has a one year low of €62.50 and a one year high of €92.97. The company has a market capitalization of €110.30 billion and a price-to-earnings ratio of 12.08.

COPYRIGHT VIOLATION WARNING: This article was posted by American Banking News and is the property of of American Banking News. If you are reading this article on another publication, it was copied illegally and republished in violation of United States & international trademark & copyright law. The original version of this article can be viewed at https://www.americanbankingnews.com/2017/06/22/j-p-morgan-chase-95-00-price-target.html.

About Sanofi SA

Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.

Receive News & Ratings for Sanofi SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi SA and related companies with MarketBeat.com's FREE daily email newsletter.